Exploring Sulpiride as an Alternative to Testosterone Propionate for Inducing Benign Prostatic Hyperplasia in Rodent
Solomon Owumi1, Esther M Pius1, Hikmah A Abdulganiyu1
1Cancer Research and Molecular Biology Research Laboratories, Department of Biochemistry, University of Ibadan, Ibadan 200005, Oyo State, Nigeria.
Toxics
|February 26, 2026
Summary
The sulpiride model is recommended for inducing benign prostatic hyperplasia (BPH) in rodents, offering a readily accessible and clinically relevant alternative to the Testosterone Propionate (TP) model for BPH research.
Area of Science:
- Urology and Andrology
- Experimental Pathology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common health issue in aging men.
- Testosterone Propionate (TP) is a standard but controlled substance for inducing BPH in rodent models.
- Controlled substance status of TP necessitates exploring alternative BPH induction models.
Purpose of the Study:
- To compare the Testosterone Propionate (TP) and sulpiride models for inducing benign prostatic hyperplasia (BPH) in experimental rodents.
- To evaluate the accessibility, mechanisms, and clinical relevance of both BPH induction models.
- To assess the toxicological profiles of the sulpiride model.
Main Methods:
- Comprehensive literature search across PubMed/MEDLINE, Embase, and Web of Science.
- Inclusion criteria focused on studies inducing BPH using either testosterone or sulpiride models.
- Thematic data extraction and appraisal of study design, rigor, and plausibility.
Main Results:
- TP model involves castrated rodents receiving injections, leading to DHT-mediated epithelial hyperplasia.
- Sulpiride model is non-invasive, uses intact animals, and induces hyperprolactinemia-mediated BPH affecting stromal and epithelial proliferation.
- Sulpiride model closely mimics human BPH pathogenesis and offers better accessibility compared to the TP model.
Conclusions:
- The sulpiride model is a viable and recommended alternative for BPH induction and study due to its accessibility and closer resemblance to human disease.
- The TP model, while established, presents logistical challenges due to drug control status and requires animal castration.
- Further examination of sulpiride's toxicological effects on organs like the kidney, liver, and reproductive system is warranted.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).